Cargando…

Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy

To evaluate the impact of mutations at reverse transcriptase codon 135 on treatment outcomes in patients receiving NNRTI-based antiretroviral therapy, a total of 68 patients (30 with and 38 without baseline mutations at codon 135) were evaluated. Median increases in CD4 counts were 135 and 90 cells/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tossonian, Harout K, Raffa, Jesse D, Grebely, Jason, Viljoen, Mark, Mead, Annabel, Khara, Milan, McLean, Mark, Krishnamurthy, Ashok, DeVlaming, Stanley, Conway, Brian
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd. 2007
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675547/ https://www.ncbi.nlm.nih.gov/pubmed/19440454 http://dx.doi.org/10.2174/1874357900701010008

Ejemplares similares

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

Identification of the Critical Sites of NNRTI-Resistance in Reverse Transcriptase of HIV-1 CRF_BC Strains
por: Huang, Yang, et al.
Publicado: (2014)

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs
por: Ha, Betty, et al.
Publicado: (2021)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
por: Jordaan, Maryam A., et al.
Publicado: (2020)

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved
por: Benedicto, Ana M., et al.
Publicado: (2021)

Healthcare resource utilization and costs associated with renal, bone and cardiovascular comorbidities among persons living with HIV compared to the general population in Quebec, Canada
por: Baribeau, Véronique, et al.
Publicado: (2022)

A Qualitative Assessment of Clinical Practice Guidelines and Patterns for Congenital Cytomegalovirus in the United States
por: Kalb, Stephanie, et al.
Publicado: (2023)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

The Codon Statistics Database: A Database of Codon Usage Bias
por: Subramanian, Krishnamurthy, et al.
Publicado: (2022)

Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
por: Beck, Eduard J., et al.
Publicado: (2011)

Expression of Codon-Optimized Gene Encoding Murine Moloney Leukemia Virus Reverse Transcriptase in Escherichia coli
por: Nuryana, Isa, et al.
Publicado: (2022)

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

1590. Resistance to Etravirine, Doravine and Rilpivirine in People Living with HIV Experiencing Virologic Failure to a First-line Antiretroviral Regimen Based on a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in a Latin American Country.
por: Mingrone, Verónica, et al.
Publicado: (2023)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

2507. Transmitted and Acquired NNRTI Resistance in the Philippines: Are Newer Generation NNRTIs a Viable Option?
por: Theresa Dungca, Nina, et al.
Publicado: (2019)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
por: Mori, J, et al.
Publicado: (2010)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Emergency of Primary NNRTI Resistance Mutations without Antiretroviral Selective Pressure in a HAART-Treated Child
por: Machado, Elizabeth S., et al.
Publicado: (2009)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection
por: Margolick, Joseph B., et al.
Publicado: (2015)

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
por: Bunupuradah, Torsak, et al.
Publicado: (2011)

Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation
por: Lapkouski, Mikalai, et al.
Publicado: (2013)

Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina
por: Rodriguez-Rodrigues, Nahuel, et al.
Publicado: (2013)

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2017)

Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels
por: Parienti, Jean-Jacques, et al.
Publicado: (2008)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

Chromosome 11q13.5 variant associated with childhood eczema: An effect supplementary to filaggrin mutations
por: O'Regan, Gráinne M., et al.
Publicado: (2010)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI
por: Liu, Shengnan, et al.
Publicado: (2023)

633. Nanopore Sequencing and In-house Bioinformatic Pipeline for Rapid and Accurate Detection of NRTI, NNRTI, PI, and INSTI Drug Resistance Mutations
por: Salvaña, Edsel Maurice, et al.
Publicado: (2023)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase
por: Penta, Ashok, et al.
Publicado: (2013)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t1s897peu0f7fror1udvq531tn